Biogen (BIIB)
(Delayed Data from NSDQ)
$131.95 USD
+3.95 (3.09%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $131.93 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Biogen Inc. has a market cap of $18.76B, which represents its share price of $128.00 multiplied by its outstanding shares number of 146.53M. As a large-cap company, BIIB's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
BIIB 131.95 +3.95(3.09%)
Will BIIB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIIB
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates
Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Other News for BIIB
Earnings Scorecard: 18 out of 21 healthcare firms beat earnings forecast this week
Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio
RBC Capital Boosts Biogen (BIIB) Price Target After Strong Q2 Earnings
RBC Capital Raises Price Target for Biogen (BIIB) to $219 | BIIB Stock News
Biogen (BIIB) Price Target Adjusted Amid Growth Concerns